ESR1 and neoplasm: Importantly, data from preclinical models show that the anti-ER drug fulvestrant markedly increases the response of ER-positive tumours to PI3Kα inhibition, resulting in major tumour regression in in vivo animal models, suggesting that combined PI3K and ER inhibition is a rational approach to target such tumours.